NAFLD in the 20’s. From Epidemiology to Pathogenesis and Management of Nonalcoholic Fatty Liver Disease

Author(s): Amedeo Lonardo, Giovanni Targher.

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 10 , 2020

Become EABM
Become Reviewer

[1]
Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
[2]
Eslam M, Sanyal AJ, George J. an international consensus panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020.Feb 7; published online ahead of print, doi:.
[http://dx.doi.org/10.1053/j.gastro.2019.11.312]
[3]
Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020.Jan 30; published online ahead of print, doi:.
[http://dx.doi.org/10.1016/j.metabol.2020.154170]
[4]
Arshad Golabi P, Henry L, Younossi ZM. Epidemiology of non-alcoholic fatty liver disease in North America. Curr Pharm Des 2020; 26(10): 993-7.
[5]
Cespiati A, Youngson NA, Tourna A, Valenti L. Genetics and epigenetics in the clinic: precision medicine in the management of fatty liver disease. Curr Pharm Des 2020; 26(10): 998-1009.
[6]
Lombardi R, Fargion S, Fracanzani AL. Combined use of genetic polymorphisms and elastographic techniques in NAFLD. Fact or fiction? Curr Pharm Des 2020; 26(10): 1010-8.
[7]
Sachinidis A, Doumas M, Imprialos K, Stavropoulos K, Katsimardou A, Athyros VG. Dysmetabolic iron overload in metabolic syndrome. Curr Pharm Des 2020; 26(10): 1019-24.
[8]
Rametta R, Fracanzani AL, Fargion S, Dongiovanni P. Dysmetabolic hyperferritinemia and dysmetabolic iron overload syndrome (DIOS): two related conditions or different entities? Curr Pharm Des 2020; 26(10): 1025-34.
[9]
Spinosa M, Stine JG. Nonalcoholic fatty liver disease – evidence for a thrombophilic state. Curr Pharm Des 2020; 26(10): 1036-44.
[10]
Mantovani A, Zusi C, Dalbeni A, Grani G, Buzzetti E. Risk of kidney dysfunction in NAFLD. Curr Pharm Des 2020; 26(10): 1045-61.
[11]
Nasr P, Blomdahl J, Kechagias S, Ekstedt M. Modifiers of liver-related manifestation in the course of NAFLD. Curr Pharm Des 2020; 26(10): 1062-78.
[12]
Johnston MP, Patel J, Byrne CD. Causes of mortality in non-alcoholic fatty liver disease (NAFLD) and alcohol related fatty liver disease (AFLD). Curr Pharm Des 2020; 26(10): 1079-92.
[13]
Craciun A, Lackner C, Cortez-Pinto H. Nonalcoholic fatty liver disease versus alcoholic liver disease: is it really so different? Curr Pharm Des 2020; 26(10): 1093-109.
[14]
Petroni ML, Brodosi L, Barbanti FA, Domizio S, Petta S, Marchesini G. Lifestyle changes for the treatment of nonalcoholic fatty liver disease - A 2015-19 update. Curr Pharm Des 2020; 26(10): 1110-8.
[15]
Bertrando S, Vajro P. NAFLD at the interface of the mother-infant dyad. Curr Pharm Des 2020; 26(10): 1119-25.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 10
Year: 2020
Page: [991 - 992]
Pages: 2
DOI: 10.2174/138161282610200424091752

Article Metrics

PDF: 22
HTML: 3